JP2024016209A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024016209A5 JP2024016209A5 JP2023191381A JP2023191381A JP2024016209A5 JP 2024016209 A5 JP2024016209 A5 JP 2024016209A5 JP 2023191381 A JP2023191381 A JP 2023191381A JP 2023191381 A JP2023191381 A JP 2023191381A JP 2024016209 A5 JP2024016209 A5 JP 2024016209A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- ctla
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063023554P | 2020-05-12 | 2020-05-12 | |
| US63/023,554 | 2020-05-12 | ||
| JP2022554243A JP7387912B2 (ja) | 2020-05-12 | 2021-05-12 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
| PCT/EP2021/062695 WO2021228978A1 (en) | 2020-05-12 | 2021-05-12 | Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554243A Division JP7387912B2 (ja) | 2020-05-12 | 2021-05-12 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024016209A JP2024016209A (ja) | 2024-02-06 |
| JP2024016209A5 true JP2024016209A5 (enExample) | 2024-05-08 |
Family
ID=75977756
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554243A Active JP7387912B2 (ja) | 2020-05-12 | 2021-05-12 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
| JP2023191381A Pending JP2024016209A (ja) | 2020-05-12 | 2023-11-09 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554243A Active JP7387912B2 (ja) | 2020-05-12 | 2021-05-12 | 免疫チェックポイント阻害剤抗体を使用した癌の処置のための方法及び組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20210355224A1 (enExample) |
| EP (1) | EP4021940A1 (enExample) |
| JP (2) | JP7387912B2 (enExample) |
| KR (1) | KR20230009354A (enExample) |
| CN (1) | CN114729054A (enExample) |
| AU (3) | AU2021269832B2 (enExample) |
| BR (1) | BR112022021893A2 (enExample) |
| CA (2) | CA3158607A1 (enExample) |
| IL (3) | IL328607A (enExample) |
| MX (1) | MX2022006728A (enExample) |
| TW (2) | TWI870592B (enExample) |
| WO (1) | WO2021228978A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260077026A1 (en) * | 2022-09-07 | 2026-03-19 | The University Of Chicago | Methods for treating cancer with hyperactive adar enzymes |
| WO2025211692A1 (ko) * | 2024-04-02 | 2025-10-09 | (주)에트노바테라퓨틱스 | 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트 |
| TW202617179A (zh) * | 2024-06-13 | 2026-05-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗pd-l1抗體和抗ctla-4抗體聯合治療腫瘤 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US20040042972A1 (en) | 2002-04-11 | 2004-03-04 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
| WO2003087339A2 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for pulmonary administration |
| EP1494651A4 (en) | 2002-04-11 | 2010-10-13 | Medimmune Vaccines Inc | PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM |
| JP2006512102A (ja) | 2002-04-11 | 2006-04-13 | メディミューン・ヴァクシンズ・インコーポレーテッド | 噴霧乾燥による生物活性材料の防腐 |
| KR20050088175A (ko) | 2002-12-17 | 2005-09-02 | 메드이뮨 백신즈 인코포레이티드 | 생물활성 물질의 고압 분무 건조 |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| SG11201702401RA (en) * | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| US20180079814A1 (en) * | 2015-04-01 | 2018-03-22 | Medimmune Limited | Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer |
| JP7085709B2 (ja) * | 2016-06-20 | 2022-06-17 | エフ－スター セラピューティクス リミテッド | Ｐｄ－ｌ１及びｌａｇ－３に結合する結合分子 |
| JP2019537619A (ja) * | 2016-09-27 | 2019-12-26 | オンコロジー、インコーポレイテッド | β２−糖タンパク質１のレベルに基づいて、バビツキシマブで癌を治療するための方法、およびそのためのアッセイ |
| KR20200020662A (ko) * | 2017-04-03 | 2020-02-26 | 온콜로지, 인크. | 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법 |
| AU2018273988C1 (en) * | 2017-05-26 | 2025-11-13 | Bruin Biosciences, Inc. | Chemoembolization agents |
| CN110914302A (zh) * | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| US20210260051A1 (en) * | 2018-06-14 | 2021-08-26 | Board Of Regents, The University Of Texas System | Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer |
| CA3102334A1 (en) * | 2018-06-15 | 2019-12-19 | Mina Therapeutics Limited | Combination therapies comprising c/ebp alpha sarna |
-
2021
- 2021-05-12 IL IL328607A patent/IL328607A/en unknown
- 2021-05-12 US US17/318,017 patent/US20210355224A1/en active Pending
- 2021-05-12 KR KR1020227024530A patent/KR20230009354A/ko not_active Ceased
- 2021-05-12 US US17/765,585 patent/US20220363762A1/en active Pending
- 2021-05-12 JP JP2022554243A patent/JP7387912B2/ja active Active
- 2021-05-12 MX MX2022006728A patent/MX2022006728A/es unknown
- 2021-05-12 TW TW110117153A patent/TWI870592B/zh active
- 2021-05-12 IL IL297640A patent/IL297640B1/en unknown
- 2021-05-12 TW TW114101922A patent/TW202535468A/zh unknown
- 2021-05-12 CN CN202180006543.2A patent/CN114729054A/zh active Pending
- 2021-05-12 CA CA3158607A patent/CA3158607A1/en active Pending
- 2021-05-12 CA CA3309448A patent/CA3309448A1/en active Pending
- 2021-05-12 WO PCT/EP2021/062695 patent/WO2021228978A1/en not_active Ceased
- 2021-05-12 BR BR112022021893A patent/BR112022021893A2/pt not_active Application Discontinuation
- 2021-05-12 EP EP21726376.3A patent/EP4021940A1/en active Pending
- 2021-05-12 AU AU2021269832A patent/AU2021269832B2/en active Active
- 2021-05-12 IL IL311936A patent/IL311936A/en unknown
-
2023
- 2023-11-09 JP JP2023191381A patent/JP2024016209A/ja active Pending
-
2024
- 2024-03-28 US US18/620,387 patent/US20240239893A1/en active Pending
- 2024-05-03 AU AU2024202963A patent/AU2024202963B2/en active Active
- 2024-11-28 AU AU2024266949A patent/AU2024266949A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2022537551A5 (enExample) | ||
| JP2024530310A (ja) | Ｔ細胞リンパ腫治療薬の調製におけるｅｚｈ２阻害剤の使用 | |
| JP2007515469A5 (enExample) | ||
| JP2023524359A5 (enExample) | ||
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| JP2011507932A5 (enExample) | ||
| JP2022512851A5 (enExample) | ||
| RU2018146812A (ru) | Фармацевтические комбинации | |
| JP2022518232A5 (enExample) | ||
| JP2018522028A5 (enExample) | ||
| JP2021509395A5 (enExample) | ||
| JP2024517085A5 (enExample) | ||
| JP2017537927A5 (enExample) | ||
| JP2023545084A5 (enExample) | ||
| JP2023510199A5 (enExample) | ||
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JP2021511344A5 (enExample) | ||
| JP2022501332A5 (enExample) | ||
| JP2023531200A5 (enExample) | ||
| JP2024531799A5 (enExample) | ||
| JP2024503379A5 (enExample) | ||
| JP2023531090A5 (enExample) | ||
| JP2022512158A5 (enExample) | ||
| JP2024535880A5 (enExample) |